Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSK | P41240 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070087 | 1.00 | CSK (0.33) | CSKCYP3A4SLC7A5NLNP2RX7 | |
| SCHEMBL3268628 | 0.87 | OPRD1 (0.33) | — | |
| SCHEMBL4197031 | 0.87 | CSK (0.45) | CSKCYP3A4SLC7A5NLNCYP1A2 | |
| SCHEMBL11620101 | 0.87 | CSK (0.45) | CSKCYP3A4SLC7A5NLNCYP1A2 | |
| SCHEMBL30745117 | 0.86 | CSK (0.32) | CSKCYP3A4SLC7A5NLN | |
| SCHEMBL14151247 | 0.86 | NLN (0.39) | NLN | |
| SCHEMBL3835499 | 0.86 | LTA4H (0.33) | CSKCYP3A4SLC7A5NLN | |
| SCHEMBL6957264 | 0.86 | CSK (0.32) | CSKCYP3A4SLC7A5NLN | |
| SCHEMBL3835494 | 0.86 | LTA4H (0.33) | CSKCYP3A4SLC7A5NLN | |
| SCHEMBL27913327 | 0.84 | CYP3A4 (0.33) | CSKCYP3A4SLC7A5NLNCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184926-A | Amino acid functionalized chiral covalent organic framework material and preparation and application thereof | 周口师范学院 | 2024-06-14 | — | — | CN | claimed |
| US-4138292-A | ENZYMES OR MICROORGANISMS IN A SULFATED POLYSACCHARIDE GEL | TANABE SEIYAKU CO., LTD. (JP) | 1979-02-06 | — | — | US | claimed |
| CN-118184926-A | Amino acid functionalized chiral covalent organic framework material and preparation and application thereof | 周口师范学院 | 2024-06-14 | — | — | CN | disclosed |
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1855544-B1 | GELATION OF ANIONIC POLYSACCARIDES USING PROTEIN HYDROLYSATES | UNILEVER NV (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| EP-1494993-B1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIV NORTH CAROLINA (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1494993-A4 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIV NORTH CAROLINA (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050187255-A1 | Novel curcumin analogues and uses thereof | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2005-08-25 | — | — | US | disclosed |
| EP-1494993-A2 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6790979-B2 | USE AS ANTITUMOR AGENTS, PARTICULARLY FOR THE TREATMENT OF CANCERS SUCH AS COLON, SKIN AND PROSTATE CANCER AND TO INDUCE ANDROGEN RECEPTOR ANTAGONIST ACTIVITY IN SUBJECT WITH ANDROGEN-RELATED AFFLICTION | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-09-14 | — | — | US | disclosed |
| WO-2003088927-A2 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030203933-A1 | Novel curcumin analogues and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-30 | — | — | US | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0123444-A1 | 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4138292-A | ENZYMES OR MICROORGANISMS IN A SULFATED POLYSACCHARIDE GEL | TANABE SEIYAKU CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | CSK 4018/4885CYP3A4 1295/4885SLC7A5 4495/4885 |
| US-20050187255-A1 | Novel curcumin analogues and uses thereof | AR, NR5A1, BRDT | CSK 4018/4885CYP3A4 1295/4885SLC7A5 4495/4885 |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | CSK 4018/4885CYP3A4 1295/4885SLC7A5 4495/4885 |
| US-20030203933-A1 | Novel curcumin analogues and uses thereof | AR, NR5A1, BRDT | CSK 4018/4885CYP3A4 1295/4885SLC7A5 4495/4885 |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | CSK 4018/4885CYP3A4 1295/4885SLC7A5 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.